96044-43-8

Basic information

• Product Name: 4-(2-hydroxyethyl)benzyl broMide
• Synonyms: 4-(2-hydroxyethyl)benzyl broMide
• CAS NO: 96044-43-8
• Molecular Formula: C₉H₁₁BrO
• Molecular Weight: 215.08704
• Mol File: 96044-43-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(2-hydroxyethyl)benzyl broMide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-hydroxyethyl)benzyl broMide(96044-43-8)
• EPA Substance Registry System: 4-(2-hydroxyethyl)benzyl broMide(96044-43-8)

Safety Data

• Hazardous Substances Data: 96044-43-8(Hazardous Substances Data)

Upstream product

• 13737-36-5 4-bromophenylacetic acid 
• 622-47-9 4-tolylacetic acid 
• 999-97-3 1,1,1,3,3,3-hexamethyl-disilazane 
• 60-12-8 2-phenylethanol 
• 74-95-3 1,1-dibromomethane 

Downstream Products

• 701911-43-5 [2-(4-bromo-methylphenyl)ethoxy]-tert-butyldiphenylsilane 
• 925418-96-8 2-{4-[(benzyl-methyl-amino)-methyl]-phenyl}-ethanol 

Relevant articles and documents

Synthesis, biological evaluation and SAR of naftopidil-based arylpiperazine derivatives

For the development of potential anti-prostate cancer agents, 24 kinds of novel naftopidil-based arylpiperazine derivatives have been synthesized and characterized by spectroscopic methods. Their antitumor activities were evaluated against several classic

Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines

A series of novel arylpiperazine derivatives was synthesized. The in vitro cytotoxic activities of all synthesized compounds against three human prostate cancer cell lines (PC-3, LNCaP, and DU145) were evaluated by a CCK-8 assay. Compounds 8, 10, 13, 17 a

Synthesis, structure-activity relationship and biological evaluation of novel arylpiperzines as α1A/1D-AR subselective antagonists for BPH

A series of novel arylpiperazine derivatives as α1A/1D-adrenergic receptors (AR) subtype selective antagonists were designed, synthesized and evaluated for their antagonistic activities towards α1-ARs (α1A, α1B,

Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines

A series of novel arylpiperazine derivatives was synthesized. The in vitro cytotoxic activities of all synthesized compounds against three human prostate cancer cell lines (PC-3, LNCaP, and DU145) were evaluated by a CCK-8 assay. Compounds 10, 24 and 29 e

Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents

A novel scaffold of arylpiperazine derivatives was discovered as potent androgen receptor (AR) antagonist through rational drug designation based on our pre-work, leading to the discovery of a series of new antiproliferative compounds. Compounds 10, 16, 2

Synthesis and cytotoxic activity evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines

A series of novel arylpiperazine derivatives was synthesized. The in vitro cytotoxic activities of all synthesized compounds against three human prostate cancer cell lines (PC-3, LNCaP, and DU145) were evaluated by a CCK-8 assay. Compounds 9 and 15 exhibi

FENTANYL HAPTENS FOR THE PREPARATION OF A FENTANYL VACCINE

Described is the preparation of novel fentanyl haptens of Formula (1) through (6) and their use in the preparation of effective fentanyl vaccines.

PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE

The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

Compounds and Their Use in Treating Cancer

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

ESTROGEN RECEPTOR-MODULATING COMPOUNDS

Described herein are compounds that are estrogen receptor modulators of formula I' Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.